$24.44
+0.21
(+0.87%)▲
1.96%
Downside
Day's Volatility :3.7%
Upside
1.77%
68.9%
Downside
52 Weeks Volatility :70.29%
Upside
4.46%
Period | Harrow Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 130.1% | 6.5% | 0.0% |
6 Months | 149.54% | 7.1% | 0.0% |
1 Year | 13.81% | 9.8% | 0.0% |
3 Years | 185.06% | 14.2% | -20.2% |
Market Capitalization | 844.6M |
Book Value | $1.71 |
Earnings Per Share (EPS) | -0.91 |
Wall Street Target Price | 29.15 |
Profit Margin | -22.59% |
Operating Margin TTM | -20.03% |
Return On Assets TTM | -1.79% |
Return On Equity TTM | -76.67% |
Revenue TTM | 138.7M |
Revenue Per Share TTM | 4.09 |
Quarterly Revenue Growth YOY | 32.5% |
Gross Profit TTM | 63.2M |
EBITDA | 4.2M |
Diluted Eps TTM | -0.91 |
Quarterly Earnings Growth YOY | -0.64 |
EPS Estimate Current Year | -0.54 |
EPS Estimate Next Year | 0.68 |
EPS Estimate Current Quarter | -0.2 |
EPS Estimate Next Quarter | -0.14 |
What analysts predicted
Upside of 19.27%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 41.4M | ↑ 54.52% |
Net Income | 14.6M | ↓ 222.03% |
Net Profit Margin | 35.35% | ↑ 80.11% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 51.2M | ↑ 23.67% |
Net Income | -2.6M | ↓ 117.72% |
Net Profit Margin | -5.07% | ↓ 40.42% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 48.9M | ↓ 4.48% |
Net Income | -3.4M | ↑ 31.91% |
Net Profit Margin | -7.0% | ↓ 1.93% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 72.5M | ↑ 48.3% |
Net Income | -18.0M | ↑ 426.67% |
Net Profit Margin | -24.85% | ↓ 17.85% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 88.6M | ↑ 22.24% |
Net Income | -14.1M | ↓ 21.77% |
Net Profit Margin | -15.9% | ↑ 8.95% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 130.2M | ↑ 46.95% |
Net Income | -24.4M | ↑ 73.3% |
Net Profit Margin | -18.75% | ↓ 2.85% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 20.3M | ↓ 10.93% |
Net Income | 1.1M | ↓ 116.32% |
Net Profit Margin | 5.19% | ↑ 33.51% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 26.1M | ↑ 28.4% |
Net Income | -6.6M | ↓ 729.67% |
Net Profit Margin | -25.45% | ↓ 30.64% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 33.5M | ↑ 28.22% |
Net Income | -4.2M | ↓ 36.34% |
Net Profit Margin | -12.64% | ↑ 12.81% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 34.3M | ↑ 2.38% |
Net Income | -4.4M | ↑ 3.83% |
Net Profit Margin | -12.81% | ↓ 0.17% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 36.4M | ↑ 6.1% |
Net Income | -9.1M | ↑ 108.34% |
Net Profit Margin | -25.16% | ↓ 12.35% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 34.6M | ↓ 4.86% |
Net Income | -13.6M | ↑ 48.28% |
Net Profit Margin | -39.22% | ↓ 14.06% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 49.5M | ↑ 106.76% |
Total Liabilities | 24.7M | ↑ 15.95% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 59.1M | ↑ 19.48% |
Total Liabilities | 31.7M | ↑ 28.21% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 57.5M | ↓ 2.73% |
Total Liabilities | 30.6M | ↓ 3.22% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 98.3M | ↑ 71.08% |
Total Liabilities | 87.4M | ↑ 185.19% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 157.0M | ↑ 59.69% |
Total Liabilities | 130.1M | ↑ 48.9% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 311.8M | ↑ 98.54% |
Total Liabilities | 241.8M | ↑ 85.77% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 157.0M | ↑ 58.62% |
Total Liabilities | 130.1M | ↑ 32.62% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 217.5M | ↑ 38.51% |
Total Liabilities | 196.0M | ↑ 50.59% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 224.0M | ↑ 2.98% |
Total Liabilities | 201.9M | ↑ 3.04% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 286.1M | ↑ 27.71% |
Total Liabilities | 210.7M | ↑ 4.32% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 311.8M | ↑ 8.98% |
Total Liabilities | 241.8M | ↑ 14.76% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 295.1M | ↓ 5.35% |
Total Liabilities | 235.3M | ↓ 2.66% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 687.0K | ↓ 107.8% |
Investing Cash Flow | -2.2M | ↑ 128.82% |
Financing Cash Flow | 4.1M | ↓ 16.21% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 950.0K | ↑ 38.28% |
Investing Cash Flow | -1.8M | ↓ 16.64% |
Financing Cash Flow | -1.0M | ↓ 124.35% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -1.1M | ↓ 215.79% |
Investing Cash Flow | -981.0K | ↓ 46.48% |
Financing Cash Flow | 1.4M | ↓ 242.45% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 5.1M | ↓ 562.0% |
Investing Cash Flow | -18.7M | ↑ 1804.79% |
Financing Cash Flow | 51.5M | ↑ 3491.77% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.7M | ↓ 66.45% |
Investing Cash Flow | -1.7M | ↓ 90.67% |
Financing Cash Flow | 54.1M | ↑ 5.19% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -3.7M | ↑ 805.37% |
Investing Cash Flow | -5.0K | ↓ 99.53% |
Financing Cash Flow | 55.0M | ↑ 0.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -8.2M | ↑ 121.28% |
Investing Cash Flow | -131.0M | ↑ 2619300.0% |
Financing Cash Flow | 62.2M | ↑ 12.96% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 4.6M | ↓ 155.59% |
Investing Cash Flow | -1.2M | ↓ 99.05% |
Financing Cash Flow | 189.0K | ↓ 99.7% |
Sell
Neutral
Buy
Harrow Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Harrow Inc | 13.54% | 149.54% | 13.81% | 185.06% | 187.43% |
![]() Neurocrine Biosciences Inc. | 7.56% | 2.78% | 45.55% | 52.55% | 67.01% |
![]() Haleon Plc Spon Ads | 7.53% | 11.87% | 3.28% | 23.35% | 23.35% |
![]() Zoetis Inc. | 5.77% | -5.62% | -5.85% | -9.99% | 57.03% |
![]() Viatris Inc. | 12.75% | -1.42% | 12.21% | -15.03% | -28.03% |
![]() Catalent, Inc. | 4.08% | 11.91% | 19.53% | -48.27% | 2.08% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Harrow Inc | NA | NA | NA | -0.54 | -0.77 | -0.02 | NA | 1.71 |
![]() Neurocrine Biosciences Inc. | 39.75 | 39.75 | 0.44 | 3.99 | 0.18 | 0.1 | NA | 23.72 |
![]() Haleon Plc Spon Ads | 29.9 | 29.9 | 1.69 | 0.39 | 0.07 | 0.04 | 0.02 | 1.8 |
![]() Zoetis Inc. | 34.62 | 34.62 | 2.58 | 5.77 | 0.5 | 0.14 | 0.01 | 11.07 |
![]() Viatris Inc. | 224.4 | NA | 0.06 | 2.73 | 0.0 | 0.03 | 0.04 | 16.81 |
![]() Catalent, Inc. | 211.02 | NA | 2.06 | 0.2 | -0.28 | -0.01 | NA | 19.96 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Harrow Inc | Buy | $844.6M | 187.43% | NA | -22.59% |
![]() Neurocrine Biosciences Inc. | Buy | $14.7B | 67.01% | 39.75 | 18.65% |
![]() Haleon Plc Spon Ads | Buy | $41.0B | 23.35% | 29.9 | 9.64% |
![]() Zoetis Inc. | Buy | $82.0B | 57.03% | 34.62 | 27.38% |
![]() Viatris Inc. | Hold | $14.2B | -28.03% | 224.4 | -0.37% |
![]() Catalent, Inc. | Hold | $10.6B | 2.08% | 211.02 | -28.44% |
Insights on Harrow Inc
Revenue is down for the last 2 quarters, 36.35M → 34.58M (in $), with an average decrease of 4.9% per quarter
Netprofit is down for the last 4 quarters, -4.22M → -13.56M (in $), with an average decrease of 53.5% per quarter
In the last 1 year, Neurocrine Biosciences Inc. has given 45.5% return, outperforming this stock by 31.7%
Opaleye Management Inc
Private Capital Management, LLC
BlackRock Inc
Vanguard Group Inc
Morgan Stanley - Brokerage Accounts
Geode Capital Management, LLC
harrow health, inc., together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the united states. the company primarily provides ophthalmology based formulations to physicians and patients; and sterile and non-sterile compounded medications. it also develops and commercializes therapeutics for treating ocular surface diseases; and non-intravenous sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. its products portfolio includes topical eye drop drug candidates, including surf-100 and surf-200; surf-300, an oral capsule for treating patients suffering from ocular surface diseases, and ded signs and symptoms; klarity drops to protect and rehabilitate the ocular surface pathology for patients with ded; melt-100, a drug that is administered sublingually for conscious sedation during cataract surgery; may-66 that is used for the treatment of symptoms associated with peyronie's diseas
Organization | Harrow Inc |
Employees | 315 |
CEO | Mr. Mark L. Baum J.D. |
Industry | Health Technology |
A Spac I Acquisition Corp
$24.44
+0.87%
Keyarch Acquisition Corp
$24.44
+0.87%
Connexa Sports Technologies Inc
$24.44
+0.87%
Us Value Etf
$24.44
+0.87%
First Wave Biopharma Inc
$24.44
+0.87%
Global X Msci Next Emerging
$24.44
+0.87%
Fat Projects Acquisition Corp
$24.44
+0.87%
Capital Link Global Fintech
$24.44
+0.87%
Applied Uv Inc
$24.44
+0.87%